HCU Updates

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

Aeglea BioTherapeutics, Inc.has announced the U.S. Food and Drug Administration (FDA)…

more

HCU Easy Tablets

Effective 1st June 2020 HCU Easy Tablets will be listed on the Pharmaceutical Benef…

more

Events

Sponsors & Partners